reference/21620976

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21620976

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	915
issn	1470-2045
issueIdentifier	7
pageRange	904-915
publicationName	The Lancet. Oncology
startingPage	904
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4b711ffdbe8af5c8f3f9c53da46d83fa
bibliographicCitation	Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904–15. doi: 10.1016/s1470-2045(18)30292-4. PMID: 29804902.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff430c1c8ca693ffb5461644ae01d90d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_372843775117894ede80c51478fa44bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfea5fc22e87c08d3141d398e3ee75d6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9630f8b97acba137bb8846de3981c92 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_233e4b940287a1de70edeef15a025eb5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_996894057ca8c04f213f4a93eff192e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0406ba536c4a8be372b1bbc6ee7b78b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e29b6fb70532ec5ed8b08df1540c7dc7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa8990245750573a9beb5a6f632541ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1804-2589 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_02d15e780f9826e74756538b50965146 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_668f3733fc2b4860cfe296199e06cd1a http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7461-1291 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd3b305a1dd7f52b1da9af7b87deea62 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9009-1572 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65b4915fc977f76d2f9754caf41b7a00 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4e9f9a74452535bc768e60519da2f46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9d5160deaf044ad0bf8a5438c61d5a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d080e10253052c10be54b9965bf128f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea9e5db787f36b5cb332b8cb340a05d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e79cda20c603bab8858626f8675bc252 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_243d87ae3c0056636969e72f3fb3bbcc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9eb672de6beed62ea552e945cfcda729 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26aefa07917c5d2286af6e42b573c141 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27391774d9cf76877f458bce79fbfa66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7e96d1e5af6a213c80c38b0f7478e71 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea8c5df146591bbcb468ca600a90398f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38fff8e271bb52fb7c7a1abc4fc36ba4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e9b2033b22ad933bf33f082f8149bb5
date	201807
identifier	https://pubmed.ncbi.nlm.nih.gov/29804902 https://doi.org/10.1016/s1470-2045%2818%2930292-4
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
discusses	http://id.nlm.nih.gov/mesh/M000640349 http://id.nlm.nih.gov/mesh/M0021024 http://id.nlm.nih.gov/mesh/M0000964 http://id.nlm.nih.gov/mesh/M000595784 http://id.nlm.nih.gov/mesh/M0028300 http://id.nlm.nih.gov/mesh/M0018169
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000631Q000008 http://id.nlm.nih.gov/mesh/D018931Q000008 http://id.nlm.nih.gov/mesh/D011687Q000008 http://id.nlm.nih.gov/mesh/D001943Q000235 http://id.nlm.nih.gov/mesh/D001943Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D038622 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D016016 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D013629Q000008 http://id.nlm.nih.gov/mesh/D009361Q000473 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D017697Q000187 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D001943Q000401 http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D000077289Q000008 http://id.nlm.nih.gov/mesh/D004311
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44631912 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311128 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5d445780815638f183c8f68566998507 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2187 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3902 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10545

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID178103955

Total number of triples: 96.